New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
Type
Journal articleSubject
3-IodobenzylguanidineAntineoplastic Agents
Combined Modality Therapy
Humans
Iodine Radioisotopes
Iodobenzenes
Neuroblastoma
Permalink
https://hdl.handle.net/10161/11047Collections
More Info
Show full item recordScholars@Duke
Michael Rod Zalutsky
Jonathan Spicehandler, M.D. Distinguished Professor of Neuro Oncology, in the School
of Medicine
The overall objective of our laboratory is the development of novel radioactive compounds
for improving the diagnosis and treatment of cancer. This work primarily involves
radiohalo-genation of biomolecules via site-specific approaches, generally via demetallation
reactions. Radionuclides utilized for imaging include I-123, I-124 and F-18, the later
two being of particular interest because they can be used for the quantification of
biochemical and physiological processes in the living huma

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info